Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | CTSS | P25774 | 9/20 | 0.37 |
| ▸ | CTSK | P43235 | 9/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12070307 | 0.90 | HDAC4 (0.41) | HDAC4HDAC1CTSLCTSSCTSK | |
| SCHEMBL15086645 | 0.81 | HDAC4 (0.41) | HDAC4HDAC1CTSLCTSSCTSK | |
| SCHEMBL12070306 | 0.78 | HDAC4 (0.40) | HDAC4HDAC1CTSLCTSSCTSK | |
| SCHEMBL15859414 | 0.75 | CTSS (0.42) | CTSLCTSS | |
| SCHEMBL15859413 | 0.75 | CTSS (0.42) | CTSLCTSS | |
| SCHEMBL3827241 | 0.75 | CTSL (0.45) | HDAC4HDAC1CTSLCTSSCTSK | |
| SCHEMBL5048335 | 0.75 | CTSL (0.43) | HDAC4HDAC1CTSLCTSSCTSK | |
| SCHEMBL6477869 | 0.74 | CTSL (0.42) | HDAC4HDAC1CTSLCTSSCTSK | |
| SCHEMBL3817398 | 0.74 | CTSL (0.46) | HDAC4HDAC1CTSLCTSSCTSK | |
| SCHEMBL5045486 | 0.73 | CTSL (0.43) | HDAC4HDAC1CTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150025250-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD | 2015-01-22 | — | — | US | disclosed |
| US-8859505-B2 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2014-10-14 | — | — | US | disclosed |
| US-20130172232-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD (GB) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025250-A1 | CYSTEINE PROTEASE INHIBITORS | CTSB, CTSS, CTRB1 | HDAC4 2279/4885HDAC1 791/4885CTSL 9/4885 |
| US-20130172232-A1 | CYSTEINE PROTEASE INHIBITORS | CTSB, CTSS, CTRB1 | HDAC4 2279/4885HDAC1 791/4885CTSL 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.